vincristine + vindesine

Vincristine + vindesine is a combination of two vinca alkaloid antineoplastic agents used in chemotherapy protocols for the treatment of various malignancies. Both drugs act as mitotic inhibitors by binding to tubulin, thereby inhibiting microtubule polymerization and arresting cell division at metaphase. Vincristine is derived from the periwinkle plant (Catharanthus roseus) and has been widely used since its discovery for treating acute lymphocytic leukemia, Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, and rhabdomyosarcoma[1][6]. Vindesine is a semisynthetic derivative of vinblastine with similar mechanisms but greater potency in causing mitotic arrest; it is indicated for pediatric solid tumors, malignant melanoma, blast crisis of chronic myeloid leukemia, acute lymphocytic leukemia resistant to vincristine, metastatic colorectal cancer, breast cancer, renal carcinoma, and esophageal carcinoma[3][4]. The combination may be considered in certain chemotherapy regimens to enhance antitumor efficacy or overcome resistance.

Other names

LeurocristineVCRDesacetylvinblastine amideVindesinum